Posted by Michael Wonder on 24 Sep 2018
Gilead subsidiary to launch authorised generics of Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C
24 September 2018 - List price of authorised generics to reflect discounts in the system today.
Gilead announced today plans to launch authorised generic versions of Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) and Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), Gilead’s leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics.
The authorised generics will launch at a list price of $24,000 for the most common course of therapy and will be available in January 2019.
